281 Oral estramustine phosphate (EMP) a broad phase II study in various solid tumors

94s

281

ORAL ESTRAMUSTINE Joshua

Halpern,

Radiation

PHOSPHATE M.D.,

E Clinical

(EMP) A BROAD PHASE

Zelig

Tochner,

Oncology,

M.D.

Hadassah

and

I I STUDY IN VARIOUS Raphael Catane, M.D.,

University

Hospital,

SOLID TUMORS. Department of

Jerusalem,

Israel.

an estradiol-nitrogen-mustard compound was EsTRAMuST~NE PHOSPHATE (ESTRAOYT NSO 89188) administered to 35 patients suffering from a wide range of advanced malignancies. Sixteen suffered from colorectal cancer, 4 from pancreatic cancer, 3 had malignant melanoma, 3 had prostatic carcinoma and 9 others had miscellaneous solid tumors. The dosage ranging between 3 and 5 tablets per drug was given orally as 140 mg tablets, day. Most of the patients were treated with EMP after becoming refractory to other resistant prostatic One had partial (>50%) remission (PR) in a hormone therapies, The (MR) were achieved. carcinoma patient and four minor (50% > x > 25%) responses two patients with colorectal cancers MR’s included another prostatic carcinoma patient, Toxicity included mainly gastrointestinal symptoms and one with malignant melanoma. and fluid retention. No myelosuppression or hepatotoxicity were encountered. EMP may colon carcinoma and malignant have a role in the treatment of prostate carcinoma, The responses seen in colorectal cancer and malignant melanoma are probably melanoma. related to the occasional presence of estrogen receptors in these diseases.

282

Long acting

LHRH analogue

in

natients

with

adenocarcinoma

Gordon Williams, J M Allen, C Smith, S R Bloom. Hammersmith Hospital & Royal Postgraduate Medlcal

School,

of

the

London,

prostate.

United

Kingdom.

The clinical and endocrine resvonse of 20 patients with advanced prostatic cancer and treated with an LHRH analogue for 3 months has been assessed. 16 showed a characteristic endocrine resDonse with an initial sustained rise in gonadotrophins and testosterone which was completely supnressed by 2 weeks. Testosterone and dihydrotestosterone have subsequently remained below castrate No alteration was found in the adrenal androgen androstanediol. levels. 4 patients showed no initial rise in testosterone and these 4 failed to respond This analogue appears to be ootent treatment for carcinoma of the clinically. Endocrine assessment is mandatory as non-resuonders may be predicted. prostate. Data on oestradiol and 5a dihydrotestosterone will also be oresented.

283

TREATMENT

OF LOCALLY+AOVANCED

PROSTATIC

CAN$$R

WITH

THE LY$H-ANALOGUE

BUSERELIN

V.Borgmann , R.Nagel , M.Schmidt-Gollwitzer H.A&nauer + Department of Urology (Head: Prof.Dr.R.Naiel), Department of Obstretics and Gynecology (Head: Prof.Dr.G.Kindermann) both Free University of Berlin, Charlottenburg, Medical Center, West-Germany +++ Med.Abt. Hoechst AG, Frankfurt/M., West-Germany 25 out of 37 patients with prostatic cancer (32 patients stage C, 2 patients stage D) were treated with the LH-RH-analogue Buserelin for 7-24 months. After an initial sequence of subcutaneous injections, treatment was continued with intranasal spray application (3x400 mcg Buserelin/die) which ensured maintenance of serum testosterone within the range seen in castrated men. To evaluate the response of the primary tuner to Buserelin, cytological regression was established by fine-needle biopsy and DNA analysis by single-cell cytophotometry every 3 month. 21 out of 25 patients treatet with Buserelin showed good therapy response, 4 patients withRno clinical signs of tumor regression received secondary treatment with Estracyt because of hormone resistence. Continous treatment of locally advance prostatic cancer with Buserelin offers not only a real alternative to surgical castration - as the patient is spared the psychical stress of orchiectomy - but also to estrogen therapy with its risk of cardiovascular side effects.